Dr. David Chang brings strong leadership and a wealth of experience in gene and cell therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy to WuXi ATU. He joins WuXi ATU from Celgene Corporation, a Bristol-Myers Squibb company where he was the Corporate Vice President and Head of Cell Therapy Global Manufacturing, and he had oversight of CAR-T manufacturing network and the global manufacturing sciences & technologies organizations.
Prior to Celgene, Dr. David Chang was the Global Head of Engineering and Strategy at Hoffmann-La Roche based, in Basel, Switzerland, and he was previously the Vice President/Site Head of Roche Shanghai Technical Operations in China.
Earlier in his career Dr. David Chang worked at Genentech as the Senior Director of Global Manufacturing Science and Technology, and as the Director of Process Development in its Oceanside, CA site. He was also formerly at Biogen Idec as Director of cell culture R&D, at BASF Bioresearch as a cell culture group leader, and at Schering-Plough Research Institute as a process development engineer.
Dr. David Chang has a B.S. degree in Chemical Engineering from National Taiwan University, and Ph.D. and master’s degree in biochemical engineering from Massachusetts Institute of Technology.
